MIRA Pharmaceuticals, Inc. - Form 8-K Filing

On December 16, 2025, the Compensation Committee of MIRA Pharmaceuticals, Inc. approved incentive awards for CEO Erez Aminov, which were ratified by the Board on December 17, 2025. These awards acknowledge the company's progress in 2025, including clinical development, capital raising, a strategic acquisition, and pipeline strengthening. The approved incentives include a short-term incentive payout of $242,258 (with an additional $80,753 contingent on a Phase 1 study completion), a transaction advisory award of $915,000 for the SKNY Pharmaceutical acquisition (payable in cash, equity, or a combination), and the issuance of 62,500 performance share units for achieving a market capitalization milestone. The Compensation Committee has instructed counsel to prepare necessary documentation and SEC filings.